Skip to Main Content

Cancer Statistics

SEER Stat Fact Sheets

Cancer: --Choose a Cancer Site-- All Sites Anus Bone and Joint Brain and Other Nervous System Breast Cervix Uteri Colon and Rectum Corpus and Uterus, NOS Esophagus Eye and Orbit Kidney and Renal Pelvis Larynx Leukemia    Acute Lymphocytic Leukemia    Chronic Lymphocytic Leukemia    Acute Myeloid Leukemia    Chronic Myeloid Leukemia Liver and Intrahepatic Bile Duct Lung and Bronchus Lymphoma    Hodgkin Lymphoma    Non-Hodgkin Lymphoma Myeloma Oral Cavity and Pharynx    Tongue Other Endocrine Ovary Pancreas Prostate Skin (excl. Basal and Squamous)    Melanoma of the Skin    Other Non-epithelial Skin Small Intestine Soft Tissue including Heart Stomach Testis Thyroid Urinary Bladder Vulva  

Note: Mortality data for the current data year is not yet available (view details).

The following information is based on NCI’s SEER Cancer Statistics Review¹X Close
Kidney and Renal Pelvis Section (http://seer.cancer.gov/csr/ 1975_2006/results_merged/ sect_11_kidney_pelvis.pdf)
.

Incidence

SEER Incidence

From 2002-2006, the median age at diagnosis for cancer of the kidney and renal pelvis was 64 years of age²X Close
Table I-11 (http://seer.cancer.gov/csr/ 1975_2006/results_single/ sect_01_table.11_2pgs.pdf). Approximately 1.3% were diagnosed under age 20; 1.5% between 20 and 34; 6.1% between 35 and 44; 16.4% between 45 and 54; 24.6% between 55 and 64; 24.3% between 65 and 74; 20.0% between 75 and 84; and 5.7% 85+ years of age.

The age-adjusted incidence rate was 13.6 per 100,000 men and women per year. These rates are based on cases diagnosed in 2002-2006 from 17 SEER geographic areas.

Trends in Rates

Trends in rates can be described in many ways. Information for trends over a fixed period of time, for example 1996-2006, can be evaluated by the annual percentage change (APC)X Close
The average annual percent change over several years. The APC is used to measure trends or the change in rates over time. For information on how this is calculated, go to Trend Algortihms in the SEER*Stat Help system. The calculation involves fitting a straight line to the natural logarithm of the data when it is displayed by calendar year. (See Fast Stats for trends over fixed time intervals) . If there is a negative sign before the number, the trend is a decrease; otherwise it is an increase. If there is an asterisk after the APC then the trend was significant, that is, one believes that it is beyond chance, i.e. 95% sure, that the increase or decrease is real over the period 1996-2006. If the trend is not significant, the trend is usually reported as stable or level. Joinpoint analysesX Close
A statistical model for characterizing cancer trends which uses statistical criteria to determine how many times and when the trends in incidence or mortality rates have changed. The results of joinpoint are given as calendar year ranges, and the annual percent change (APC) in the rates over each period can be used over a long period of time to evaluate when changes in the trend have occurred along with the APC which shows how much the trend has changed between each of the joinpoints.

Survival & Stage

Survival ratesX Close
Survival examines how long after diagnosis people live. Cancer survival is measured in a number of different ways depending on the intended purpose. Several examples of survival statistics are listed below. can be calculated by different methods for different purposes. The survival rates presented here are based on the relative survival rateX Close
A measure of net survival that is calculated by comparing observed (overall) survival with expected survival from a comparable set of people that do not have cancer to measure the excess mortality that is associated with a cancer diagnosis., which measures the survival of the cancer patients in comparison to the general population to estimate the effect of cancer. The overall 5-year relative survival rate for 1999-2005 from 17 SEER geographic areas was 68.4%. Five-year relative survival rates by race and sex were: 68.1% for white men; 69.1% for white women; 64.7% for black men; 67.4% for black women.

The stage distributionX Close
Stage provides a measure of disease progression, detailing the degree to which the cancer has advanced. Two methods commonly used to determine stage are AJCC and SEER Summary Stage. The AJCC method (see Collaborative Staging Method) is more commonly used in the clinical settings, while SEER has strived to provide consistent definitions over time with their Local/Regional/Distant staging. based on Summary Stage 2000 shows that 58% of kidney and renal pelvis cancer cases are diagnosed while the cancer is still confined to the primary site (localized stage); 18% are diagnosed after the cancer has spread to regional lymph nodes or directly beyond the primary site; 19% are diagnosed after the cancer has already metastasized (distant stage) and for the remaining 4% the staging information was unknown. The corresponding 5-year relative survival rates were: 90.4% for localized; 62.3% for regional; 10.4% for distant; and 37.5% for unstaged. (See Fast Stats for more detailed statistics)

Prevalence

On January 1, 2006, in the United States there were approximately 266,068 men and women alive who had a history of cancer of the kidney and renal pelvis -- 156,166 men and 109,902 women. This includes any person alive on January 1, 2006 who had been diagnosed with cancer of the kidney and renal pelvis at any point prior to January 1, 2006 and includes persons with active disease and those who are cured of their disease. PrevalenceX Close
The number of people who have received a diagnosis of cancer during a defined time period, and who are alive on the last day of that period. Most prevalence data in SEER is for limited duration because information on cases diagnosed before 1973 is not generally available. can also be expressed as a percentage and it can also be calculated for a specific amount of time prior to January 1, 2006 such as diagnosed within 5 years of January 1, 2006. (See Fast Stats for more detailed statistics, and Overview of Prevalence Statistics for methodology)

---

References

All statistics in this report are based on SEER incidence statistics. Most can be found within:

Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.